- Home
- KIO vs ERAS Comparison
KIO vs ERAS Comparison
Compare KIO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- ERAS
- Stock Information
- Founded
- KIO 2011
- ERAS 2018
- Country
- KIO United States
- ERAS United States
- Employees
- KIO 2400
- ERAS N/A
- Industry
- KIO Investment Managers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- KIO Finance
- ERAS Health Care
- Exchange
- KIO Nasdaq
- ERAS Nasdaq
- Market Cap
- KIO 472.0M
- ERAS 432.6M
- IPO Year
- KIO N/A
- ERAS 2021
- Fundamental
- Price
- KIO $11.45
- ERAS $1.39
- Analyst Decision
- KIO
- ERAS Strong Buy
- Analyst Count
- KIO 0
- ERAS 6
- Target Price
- KIO N/A
- ERAS $4.83
- AVG Volume (30 Days)
- KIO 136.5K
- ERAS 1.9M
- Earning Date
- KIO 01-01-0001
- ERAS 05-07-2025
- Dividend Yield
- KIO 10.82%
- ERAS N/A
- EPS Growth
- KIO N/A
- ERAS N/A
- EPS
- KIO N/A
- ERAS N/A
- Revenue
- KIO N/A
- ERAS N/A
- Revenue This Year
- KIO N/A
- ERAS N/A
- Revenue Next Year
- KIO N/A
- ERAS N/A
- P/E Ratio
- KIO N/A
- ERAS N/A
- Revenue Growth
- KIO N/A
- ERAS N/A
- 52 Week Low
- KIO $10.52
- ERAS $1.01
- 52 Week High
- KIO $13.59
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- KIO 40.27
- ERAS 47.36
- Support Level
- KIO $11.28
- ERAS $1.12
- Resistance Level
- KIO $11.48
- ERAS $1.42
- Average True Range (ATR)
- KIO 0.28
- ERAS 0.17
- MACD
- KIO 0.01
- ERAS 0.01
- Stochastic Oscillator
- KIO 49.67
- ERAS 60.49
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.